CELLTREAT Acquires VistaLab Technologies

CELLTREAT Scientific Products Acquires Brewster Plastics

November 13, 2024

Manufacturing

CELLTREAT Scientific Products has acquired Brewster Plastics, a U.S.-based precision injection molding manufacturer with a 72,000 sq. ft. facility in Patterson, New York. Operations will be consolidated with CELLTREAT's VistaLab Technologies subsidiary to expand domestic production capacity, improve delivery times, and boost manufacturing efficiency for lab consumables and plastics.

The Vistria Group Acquires BioCare, Inc.

November 8, 2021

Healthcare Services

The Vistria Group has acquired BioCare, Inc., a Tempe-based specialty pharmaceutical distributor, specialty pharmacy and pharmaceutical logistics provider. The deal is Vistria’s first investment from its $2.68 billion Fund IV and aims to support BioCare’s growth — both organically and via acquisitions — to expand access to therapies for rare and orphan diseases.

Verdesian Life Sciences Acquires Cytozyme Laboratories

April 27, 2021

Agriculture

Verdesian Life Sciences has acquired Cytozyme Laboratories, Inc.; Cascadia Capital served as exclusive financial advisor to Cytozyme. The acquisition brings together complementary biological and nutritional crop technologies to expand Verdesian's product portfolio and support sustainable yield solutions for growers.

BioIVT Acquires Valley Biomedical Products & Services

June 28, 2021

Medical Devices

BioIVT, a provider of research models and value-added research services, has acquired Valley Biomedical Products & Services, an FDA-registered manufacturer of in vitro diagnostics, sera, plasma and reagents based in Winchester, Virginia. The acquisition will expand BioIVT’s capabilities in IVD manufacturing and cell & gene therapy support by combining Valley Biomedical’s reagent and blood-product manufacturing with BioIVT’s donor centers and specimen services; BioIVT will continue operating the Winchester facility and retain its staff.

Vertex Pharmaceuticals Acquires ViaCyte for $320M

July 11, 2022

Biotechnology

Vertex Pharmaceuticals agreed to acquire clinical-stage cell therapy company ViaCyte for $320 million in cash. The deal gives Vertex additional stem cell lines, IP and GMP manufacturing capabilities intended to accelerate its VX-880 and other cell replacement therapy programs for type 1 diabetes.

Bio-Techne Acquires Namocell

June 22, 2022

Medical Devices

Bio-Techne Corporation has agreed to acquire Namocell, Inc., a Mountain View–based provider of single-cell sorting and dispensing platforms, with the deal expected to close in Bio-Techne's fiscal 2023 Q1. Namocell's Pala and Hana systems (installed base approaching 200 placements, ~60 sold in 2021) will complement Bio-Techne's Cell and Gene Therapy franchise and create commercial synergies across its analytical instruments sales force.